ADTX
Aditxt Inc
NASDAQ · Biotechnology
$0.65
+0.03 (+4.55%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 181.3K | 180.5K | 146.0K |
| Net Income | -17,696 | -19,611 | -15,138 |
| EPS | — | — | — |
| Profit Margin | -9.8% | -10.9% | -10.4% |
| Rev Growth | -0.2% | +10.1% | +10.9% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 163.3K | 133.1K | 136.4K |
| Total Equity | 126.1K | 143.0K | 117.9K |
| D/E Ratio | 1.30 | 0.93 | 1.16 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -22,705 | -25,362 | -18,933 |
| Free Cash Flow | -14,609 | -13,693 | -9,143 |